Literature DB >> 17692435

Aldehyde dehydrogenase inhibitors: alpha,beta-acetylenic N-substituted aminothiolesters are reversible growth inhibitors of normal epithelial but irreversible apoptogens for cancer epithelial cells from human prostate in culture.

Gerard Quash1, Guy Fournet, Charlotte Courvoisier, Rosa M Martinez, Jacqueline Chantepie, Marie Julie Paret, Julie Pharaboz, Marie Odile Joly-Pharaboz, Jacques Goré, Jean André, Uwe Reichert.   

Abstract

The pharmacomodulation of the N atom of alpha,beta-acetylenic aminothiolesters or the replacement of the thiolester moiety by more electrophilic groups did not permit any clear rationale to be established for improving the selective growth-inhibitory activity of this family of compounds over that of the previously synthesized alpha,beta-acetylenic aminothiolesters DIMATE and MATE [G. Quash, G. Fournet, J. Chantepie, J. Goré, C. Ardiet, D. Ardail, Y. Michal, U. Reichert, Biochem Pharmacol 64 (2002) 1279-92]. Hence DIMATE and MATE were investigated more thoroughly for selectivity and growth-inhibitory activity using human prostate epithelial normal cells (HPENC) on the one hand and human prostate epithelial cancer cells (DU145) on the other. Unequivocal evidence was obtained showing that both compounds were reversible growth inhibitors of HPENC but irreversible growth inhibitors of DU145. Growth-inhibition of DU145 was due to the induction of early apoptosis as revealed by the flow cytometric analytical profile of inhibitor-treated cells, of the decrease in the redox potential and increase in superoxide anion content of their mitochondria. Of the two intracellular enzymes: aldehyde dehydrogenases 1 and 3 (ALDH1 and ALDH3) targeted by DIMATE and MATE, ALDH3 was inhibited to the same extent by both compounds whereas ALDH1 was less susceptible to inhibition by MATE. As the induction of ALDH3 by xenobiotics is hormone-dependent, MATE, the more selective of the two inhibitors, is a useful tool not only for examining the role of the ALDH3 isoform in hormone-sensitive and resistant prostate cancer cells in culture but also for investigating if it can inhibit the growth of xenografts of prostate cancer in immunodeficient mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692435     DOI: 10.1016/j.ejmech.2007.06.004

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.

Authors:  M Pérez-Alea; K McGrail; S Sánchez-Redondo; B Ferrer; G Fournet; J Cortés; E Muñoz; J Hernandez-Losa; S Tenbaum; G Martin; R Costello; I Ceylan; V Garcia-Patos; J A Recio
Journal:  Oncogene       Date:  2017-06-05       Impact factor: 9.867

Review 2.  Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.

Authors:  Vindhya Koppaka; David C Thompson; Ying Chen; Manuel Ellermann; Kyriacos C Nicolaou; Risto O Juvonen; Dennis Petersen; Richard A Deitrich; Thomas D Hurley; Vasilis Vasiliou
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

3.  High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells.

Authors:  Patricia E Burger; Rashmi Gupta; Xiaozhong Xiong; Christopher S Ontiveros; Sarah N Salm; David Moscatelli; E Lynette Wilson
Journal:  Stem Cells       Date:  2009-09       Impact factor: 6.277

4.  Biological evaluation and 3D-QSAR studies of curcumin analogues as aldehyde dehydrogenase 1 inhibitors.

Authors:  Hui Wang; Zhiyun Du; Changyuan Zhang; Zhikai Tang; Yan He; Qiuyan Zhang; Jun Zhao; Xi Zheng
Journal:  Int J Mol Sci       Date:  2014-05-16       Impact factor: 5.923

Review 5.  Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance.

Authors:  Michele Zanoni; Sara Bravaccini; Francesco Fabbri; Chiara Arienti
Journal:  Front Med (Lausanne)       Date:  2022-03-01

6.  Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.

Authors:  G Venton; M Pérez-Alea; C Baier; G Fournet; G Quash; Y Labiad; G Martin; F Sanderson; P Poullin; P Suchon; L Farnault; C Nguyen; C Brunet; I Ceylan; R T Costello
Journal:  Blood Cancer J       Date:  2016-09-09       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.